Bavarian Nordic — Marts 2023
-
beklager...der er noget med keyboardet.
-
Den 29/4 2021 udsendte BN en pressemeddelelse vedr. prækliniske data fra ABNCoV2 vaccinen. De kom fra Rahoud University Medical Center i Holland. Og de var særdeles imponerende i forhold til mRNA vaccinerne. Den 18/3 2021 havde Michael Novod / Nordea været ude med den helt vilde forudsigelse, at såfremt BN's covid vaccine blev en succes, kunne kursen på BN's aktier nå 900 kr. Tja, det var dengang! Men der ligger selvfølgelig data klar, som givetvis også skal samkøres.
-
Langtidsaftaler kan sagtens komme først tror jeg. Den er på trapperne, efter udmeldinger. Med lidt færre resultater, grundet frafald af deltagere, men det var forventet. Fase 3 med foreløbige data (tror jeg) ca april og endelige data ca sept. hvis vi får de foreløbige data.
-
Den 23/8 2021 meddelte BN, at de igangsatte fase 2 forsøget med covid-vaccinen med 150 sunde mennesker, der havde erhvervet immunitet enten via covid smitte eller gennem vaccinatione med eksisterende vacciner. Her ville BN's vaccine skulle vise effekten af et boost af SARS-CoV-2 antibody i kroppen. Desuden fik 60 mennesker, de rikke tidligere havde været syge af covid 2 injektioner med vaccinen for at vurdere effekten af vaccinens evne til at booste immunforsvaret.
-
...harmonerer fint med min åbning på tråden, men så læste jeg lige, at primary completion date, definerers som 'The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure.'
-
så lidt forvirring der...
-
Biden administration warns of $35 billion shortfall for health emergency stockpile https://www.cbsnews.com/news/biden-administration-warns-of-35-billion-shortfall-for-health-emergency-stockpile/
-
"This year, the Biden administration hopes Congress can enshrine pandemic preparedness needs as mandatory funding, akin to military defense spending. Department officials have previously warned about challenges restocking supplies depleted for the mpox response, which used drugs and vaccines initially saved up for a potential smallpox attack."
-
Godmorgen
-
Interview med Expres2ions CEO i dag i biostock.se: “Along the way, ExpreS2ion has seen positive phase II data, and the next important milestone will be a top-line readout from the ongoing phase III study. This is expected sometime in mid-2023” https://www.biostock.se/en/2023/03/expres2ions-ceo-on-current-development-and-the-rights-issue/
-
Jeg tror desværre, at vi må vente et par måneder før der kommer store nyheder angående Covid Fase III. De er ikke klar med data før juni tidligst. Medmindre at der kommer en stor ordre på Mpox eller partneraftale angående RSV...
-
Fra samme interview: – ABNCoV2 has a very competitive Covid-19 vaccine profile for several reasons. First of all, it has shown broad protection across variants of concern. So, while the virus continues to mutate, ABNCoV2 has continued to demonstrate protection. Secondly, it has shown a durability in protection – up to six months, which is very high in this field. Protection from the leading mRNA vaccines starts to wane at 3 – 4 months, requiring numerous booster injections. Let’s see if ...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind